Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The price of Avidity Biosciences Inc (NASDAQ: RNA) closed at $32.66 in the last session, down -9.88% from day before closing price of $36.24. In other words, the price has decreased by -$9.88 from its previous closing price. On the day, 4.83 million shares were traded. RNA stock price reached its highest trading level at $38.0 during the session, while it also had its lowest trading level at $31.6.
Ratios:
We take a closer look at RNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 16.91 and its Current Ratio is at 16.91. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Buy rating and assigned the stock a target price of $70.
On March 12, 2025, BMO Capital Markets started tracking the stock assigning a Outperform rating and target price of $72.
On March 07, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $70.Scotiabank initiated its Sector Outperform rating on March 07, 2025, with a $70 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 02 ’25 when Gallagher Kathleen P. sold 5,875 shares for $32.48 per share. The transaction valued at 190,833 led to the insider holds 50,554 shares of the business.
KATHLEEN GALLAGHER bought 5,875 shares of RNA for $182,008 on Jun 02 ’25. On May 01 ’25, another insider, Gallagher Kathleen P., who serves as the Chief Program Officer of the company, sold 5,875 shares for $32.40 each. As a result, the insider received 190,324 and left with 50,554 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RNA now has a Market Capitalization of 4367654400 and an Enterprise Value of 2562879744. For the stock, the TTM Price-to-Sale (P/S) ratio is 440.85 while its Price-to-Book (P/B) ratio in mrq is 2.96. Its current Enterprise Value per Revenue stands at 287.093 whereas that against EBITDA is -5.955.
Stock Price History:
The Beta on a monthly basis for RNA is 0.95, which has changed by 0.12932229 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, RNA has reached a high of $56.00, while it has fallen to a 52-week low of $21.51. The 50-Day Moving Average of the stock is 9.89%, while the 200-Day Moving Average is calculated to be -8.89%.
Shares Statistics:
According to the various share statistics, RNA traded on average about 1.48M shares per day over the past 3-months and 1587460 shares per day over the past 10 days. A total of 120.51M shares are outstanding, with a floating share count of 109.84M. Insiders hold about 8.88% of the company’s shares, while institutions hold 107.71% stake in the company. Shares short for RNA as of 1747267200 were 15787027 with a Short Ratio of 10.64, compared to 1744675200 on 15483940. Therefore, it implies a Short% of Shares Outstanding of 15787027 and a Short% of Float of 13.22.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
